Brachiocephalic Vein Stenosis Clinical Trial
— Arch-VOfficial title:
Biomimetic (SUPERA) Stent and Drug Eluting Balloon (Passeo 18 Lux) to Treat Recurrent Cephalic Arch Stenosis
| Verified date | March 2021 |
| Source | Singapore General Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The study evaluates the use of a biomimetic stent (SUPERA®) and a drug eluting balloon (DEB - Passeo 18 Lux) for the treatment of recurrent and tight cephalic arch stenosis in patients with brachiocephalic fistulas. All participants will undergo angioplasty with stated devices, and be followed up with over 12 months.
| Status | Completed |
| Enrollment | 20 |
| Est. completion date | January 30, 2021 |
| Est. primary completion date | June 30, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years to 90 Years |
| Eligibility | Inclusion Criteria: - Patient's age is above 21 and below 90 - Informed consent obtained - Chronic background treatment with daily ASA - Patients with significant Cephalic Arch Vein Stenosis or recurrent stenosis within 6 months of initial POBA diagnosed either clinically or with Duplex Ultrasound - Post-angioplasty cephalic arch lumen size between 5mm - 7mm maximum diameter Exclusion Criteria: - Patients with significant central vein stenosis (>70%) or total occlusion at time of angiographic study - Cephalic arch stenosis <50% stenosis or diameter >5mm - Patients with previous cephalic arch stenting (Bare Metal Stents or stent graft) - Concomitant fistula inflow problem (e.g. juxta-anastomotic) that cannot be corrected optimally during the intervention (>30% residual stenosis or angiographic lumen <3mm) - Patients with minor or major cephalic arch rupture during POBA procedure and the rupture point cannot be adequately sealed off during the procedure requiring a covered stent or open conversion - Cephalic arch lesion length <10mm or greater than 10cm - Patients with uncontrolled hypertension - Patient <21 or > 90 years of age. - Pregnant women or women of childbearing potential who are not following an effective method of contraception. - Contraindication to aspirin or clopidogrel usage - Mental condition rendering the subject unable to understand the nature, scope, and possible consequences o the study, or language barrier such that the subject is unable to give informed consent. - Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical - Patients who do NOT have impaired renal function - Occluded or thrombosed fistula - Patients presenting with central venous stenosis - Final angioplasty treatment requires a stent or DEB >7mm in diameter - Multiple lesions in the access circuit that cannot be treated with one stent and DEB. - Vascular access circuit placed in the lower extremities - Bare metal stent or stent-graft placed previously - Metastatic caner or terminal medical condition - Blood coagulation disorder - Limited life expectancy (<6 months) - Sepsis or active infection - Recent arm thrombophlebitis - Allergy or other known contraindication to iodinated media contrast, heparin or paclitaxel |
| Country | Name | City | State |
|---|---|---|---|
| Singapore | Singapore General Hospital | Singapore |
| Lead Sponsor | Collaborator |
|---|---|
| Singapore General Hospital |
Singapore,
Bishu K, Armstrong EJ. Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag. 2015 Jul 13;11:387-95. doi: 10.2147/VHRM.S70229. eCollection 2015. Review. — View Citation
Cho SB, Choi HC, Bae E, Park TJ, Baek HJ, Park SE, Ryu KH, Moon JI, Choi BH, Bae K, Jeon KN. Angioplasty and stenting for the proximal anastomotic stenosis of a brachio-axillary bypass graft using a helical interwoven nitinol stent: A case report. Medicine (Baltimore). 2017 Dec;96(50):e9073. doi: 10.1097/MD.0000000000009073. — View Citation
Garcia L, Jaff MR, Metzger C, Sedillo G, Pershad A, Zidar F, Patlola R, Wilkins RG, Espinoza A, Iskander A, Khammar GS, Khatib Y, Beasley R, Makam S, Kovach R, Kamat S, Leon LR Jr, Eaves WB, Popma JJ, Mauri L, Donohoe D, Base CC, Rosenfield K; SUPERB Trial Investigators. Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial. Circ Cardiovasc Interv. 2015 May;8(5). pii: e000937. doi: 10.1161/CIRCINTERVENTIONS.113.000937. Erratum in: Circ Cardiovasc Interv. 2015 Jun;8(6). pii: e000014. doi: 10.1161/HCV.0000000000000014. — View Citation
Micari A, Brodmann M, Keirse K, Peeters P, Tepe G, Frost M, Wang H, Zeller T; IN.PACT Global Study Investigators. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study. JACC Cardiovasc Interv. 2018 May 28;11(10):945-953. doi: 10.1016/j.jcin.2018.02.019. — View Citation
Scheinert D, Werner M, Scheinert S, Paetzold A, Banning-Eichenseer U, Piorkowski M, Ulrich M, Bausback Y, Bräunlich S, Schmidt A. Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2013 Jan;6(1):65-71. doi: 10.1016/j.jcin.2012.09.011. — View Citation
Zeller T, Beschorner U, Pilger E, Bosiers M, Deloose K, Peeters P, Scheinert D, Schulte KL, Rastan A, Brodmann M. Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015 Oct;8(12):1614-22. doi: 10.1016/j.jcin.2015.07.011. — View Citation
Zhang D, Yang R, Wang S, Dong Z. Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014 Feb 20;8:279-84. doi: 10.2147/DDDT.S56801. eCollection 2014. Review. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Angiographic Success | <30% regional stenosis within the stent and minimal lumen size should reach 5mm | Immediately post-operation | |
| Primary | Functional Fistula | At the following time points, to monitor for any changes in whether fistula can be used successfully for dialysis without the need for re-intervention. | Post-operation 1 week, 2 months, 6 months and 12 months. | |
| Primary | Primary Patency of Cephalic Arch | Less than 50% stenosis observed on duplex ultrasound | 1 year post-operation | |
| Secondary | Access Circuit Thrombosis | Thrombosis of access circuit requiring further intervention such as thrombolysis | 1 year post-operation | |
| Secondary | Number of re-interventions per year | To note any re-interventions performed post-study procedure | 1 year post-operation | |
| Secondary | Access Circuit Restenosis / Stent Fractures | To note any restenosis or stent fractures during study period that requires re-intervention | 1 year post-operation | |
| Secondary | Access Circuit Infection | To note any infection at treated fistula during study period | 1 year post-operation | |
| Secondary | Need for bypass revision surgery | 1 year post-operation |